关于系统性红斑狼中心血管疾病的最新情况
Ewa Pędzich1, Adrian Bednarek1, Julita Młynarska1
1First Department of Cardiology, Medical University of Warsaw, Poland.
概括
系统性红斑狼 (SLE) 增加了心血管风险,如心脏病和中风. 本综述涵盖了诊断,管理以及SLE患者心血管风险的最新欧洲指南.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 系统性红斑狼 (SLE) 是一种慢性自身免疫性疾病,导致系统性炎症和器官损伤.
- SLE显著增加了心血管疾病的风险,包括动脉高血压,肺高血压 (PH),静脉血栓栓塞 (VTE),冠状动脉疾病 (CAD) 和脑血管事件.
- 这些心血管并发症有助于增加SLE患者的死亡率.
研究的目的:
- 审查和系统化有关SLE心血管疾病的当前数据.
- 总结最近诊断方法的进展,包括成像和生物标志物.
- 概述最新的欧洲风湿病学协会联盟 (EULAR) 关于管理SLE心血管风险的指南.
主要方法:
- 对最近文献进行系统审查.
- 分析已发布的指导方针和建议.
- 对诊断进步和治疗策略的概述.
主要成果:
- 心血管疾病在SLE患者中非常普遍.
- 诊断工具,包括先进的成像和生物标志物,已经得到了改进.
- 目前的EULAR指导方针为SLE患者的心血管风险管理提供了一个框架.
结论:
- 心血管疾病是SLE管理的一个主要问题.
- 早期诊断和积极的风险管理至关重要.
- 遵守最新的EULAR指南可以优化患者的治疗结果.
相关概念视频
Assessment of the Cardiovascular System I: Subjective Data
338
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
338
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Assessment of the Cardiovascular System II: Inspection
249
Inspection is the initial step in assessing the cardiovascular system. It involves a detailed visual examination that provides crucial information about a patient's circulatory and cardiac health. This systematic process, conducted from head to toe, helps identify signs of cardiovascular conditions by observing physical appearance, skin and mucous membranes, jugular and carotid pulsations, chest symmetry, and the condition of the extremities.
Head and Neck
Head and Neck
249
Psychoneuroimmunology: Cardiovascular Disease
30
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
30
Cardiovascular System Abnormal Findings I: Inspection and Palpation
397
In a cardiovascular examination, inspection and palpation are crucial for identifying abnormalities.
Abnormal findings observed during an inspection
Abnormal findings observed during an inspection
397
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429


